Growth hormone release in children after cranial irradiation.
Growth retardation due to growth hormone (GH) deficiency is common in children after radiotherapy to the brain. Different methods for assessment of GH secretion were compared in 19 children who had received radiotherapy to the brain as part of treatment for a tumor of the brain, eye or epipharynx. GH was measured over a 24-hour period (72 sampling periods of 20 min each), as well as after administration of growth hormone-releasing hormone (GHRH) and arginine-insulin (AITT) tests. We found the 24-hour GH profile to be disturbed in all children; there was a low overall secretion with few peaks of low amplitude but a diurnal rhythm still discernable. In 16 children a prompt rise in GHRH after GHRH1-40 was seen indicating hypothalamic damage. The GH response after GHRH was not found to be correlated to the spontaneous secretion over 24 h. The results of the AITT showed discrepancies to the 24-hour GH profile in individual cases making this test unreliable in spite of a good overall correlation between the tests. Therefore, we suggest measurement of spontaneous secretion when GH-secretory capability is to be evaluated after cranial irradiation for a brain tumor.
D000293:Adolescent; D001921:Brain / Q000528:radiation effects*; D002648:Child; D002675:Child, Preschool; D006130:Growth Disorders / Q000188:drug therapy / Q000209:etiology; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*
D010446:Peptide Fragments; C036893:somatotropin releasing factor 40; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone